Safety and Efficacy Study of PRV211 in Subjects With Oral Squamous Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
PRV211 is a sterilized nano engineered delivery system intended for intraoperative
chemotherapy treatment for all solid tumor surgeries immediately following surgical excision.
The goal is to treat the tumor bed locally, eliminating any remaining micro metastases or
close margins that are unable to be fully resected while avoiding system circulation.
This study will enroll up to 40 subjects. In this study both safety and efficacy will be
evaluated. All subjects will be monitored for possible DLTs.